Registered title, quoted from ClinicalTrials.gov
Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
An open trial on Wilson disease, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 3 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 3
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteBeijing Friendship Hospital首都医科大学附属北京友谊医院BeijingHospital page
- Study siteBeijing Youan Hospital, Capital Medical University首都医科大学附属北京佑安医院BeijingHospital page
- Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07465718, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
8 years to Not stated; sex: all
Registered eligibility fields
Participants 12 years or older at screening, Model for End stage Liver Disease (MELD) score of greater than or equal to 12.
Exclusion criterion 6
Participants 8 to 11 years at screening, Model for Pediatric End stage Liver Disease (PELD) of greater than or equal to 10
Exclusion criterion 7
Received no prescribed chelator therapy [a] for the treatment of WD (chelator-naïve); zinc salts are permitted for no more than 28 days prior to the start of screening assessments, and these participants must be symptomatic.
Inclusion criterion 6
Hemoglobin of less than or equal to 9 g/dL.
Exclusion criterion 8
Estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73m²
Exclusion criterion 9
Alanine aminotransferase greater than 5 times upper limit of normal (ULN).
Exclusion criterion 11
Active infection with hepatitis B virus (positive hepatitis B surface antigen) or C virus or seropositivity for human immunodeficiency virus (HIV).
Exclusion criterion 16
Female participants of childbearing potential, currently pregnant, currently nursing, or planning a pregnancy during study period.
Exclusion criterion 18
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; day-to-day activity level; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07465718, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Participant is aged 8 years or older and is willing and able to give informed consent for participation in the study, or by a parent/legally authorized representative (LAR) and assent obtained (in accordance with local regulations) for any participant less than the age of majority (e.g. less than 18 years of age, depending on local requirements).
- Participant has a body weight of at least 25 kg at screening.
- Participant has a diagnosis of WD, as defined by a Leipzig score of greater than or equal to 4. Note that historical test results can be used for the diagnosis.
- Participant has either:
- Received no prior prescribed therapy [a] for the treatment of WD (treatment-naïve), or
- Received no prescribed chelator therapy [a] for the treatment of WD (chelator-naïve); zinc salts are permitted for no more than 28 days prior to the start of screening assessments, and these participants must be symptomatic.
[a] prescribed therapy for WD refers to the authorized chelator treatments of trientine (TETA 2HCl or TETA 4HCl) and DPA, or zinc salts.
- Able and willing to comply with study procedures and requirements, as described in the informed consent.
- Adequate venous access to allow collection of required blood samples.
- Willing to comply with low copper diet for the duration of the study.
- Participant requires treatment for WD, in the opinion of the Investigator.
- Participant is able to take the study medication as prescribed, in the opinion of the Investigator.
Exclusion Criteria:
- Any known contraindications for treatment with DPA.
- Any known contraindications for treatment with TETA 4HCl.
- Unable to swallow tablets/capsules independently or considered high risk for aspiration, in the opinion of the Investigator
- Acute liver failure (ALF) or at high risk of ALF, in the opinion of the Investigator.
- Decompensated hepatic cirrhosis, in the opinion of the Investigator.
- Participants 12 years or older at screening, Model for End stage Liver Disease (MELD) score of greater than or equal to 12.
- Participants 8 to 11 years at screening, Model for Pediatric End stage Liver Disease (PELD) of greater than or equal to 10
- Hemoglobin of less than or equal to 9 g/dL.
- Estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73m²
- Nephritis or nephrotic syndrome, in the opinion of the Investigator.
- Alanine aminotransferase greater than 5 times upper limit of normal (ULN).
- Severe pulmonary disease requiring home nebulization and/or home oxygen therapy.
- Clinically significant gastrointestinal bleed within past 6-months.
- Neurological disease requiring either nasogastric feeding or intensive inpatient medical care.
- Active or history of seizures requiring anti-epileptics within 6 months prior to informed consent.
- Active infection with hepatitis B virus (positive hepatitis B surface antigen) or C virus or seropositivity for human immunodeficiency virus (HIV).
- Major systemic disease or other illness that would, in the opinion of the Investigator, compromise patient safety or interfere with the collection or interpretation of the study results.
- Female participants of childbearing potential, currently pregnant, currently nursing, or planning a pregnancy during study period.
- Female participants of childbearing potential, unable or unwilling to use a reliable form of contraceptive throughout the study.
- Male participants, unable or unwilling to use a reliable form of contraceptive throughout the study.
- Participant is not willing to comply with the prohibited medication requirements for the study.
- In the opinion of the Investigator, the participant is likely to be non-compliant or uncooperative for the required study visits or study assessments, or has any disease, disability, illness or abnormal laboratory values that could compromise patient safety or interfere with the collection or interpretation of study results.
Quoted from ClinicalTrials.gov, NCT07465718, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07465718, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.